Powdered Intrawound Vancomycin in Open Fractures Trial

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Manitoba

About this trial

The purpose of this randomized control trial is to compare the rate of post-operative infection in patients with open fractures in upper or lower extremity long bones randomized to receive intra-operative intrawound topical vancomycin powder on their open fractures in addition to the current best practice of intravenous antibiotics with irrigation and debridement compared to intravenous antibiotics with irrigation and debridement alone during definitive operative fixation of the fracture.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

18 years or older at time of surgery

Patients with an open fracture classified as Gustilo Type I to IIIc in the clavicle, humerus, radius, ulna, metacarpals, upper extremity phalanges (fingers), femur, tibia, fibula and metatarsals and lower extremity phalanges (toes).

Open fracture treated operatively with plate(s) and screw(s) hardware fixation and intramedullary fixation (IM nail).

Able to attend standard of care follow up for six months post-operatively

Disqualifiers

Patients with known vancomycin allergy, drug administration reaction, or other sensitivities to vancomycin.

Patients who have already had definitive fracture fixation before enrollment in the study

Patients with open fracture already infected at time of enrollment

Patients with current positive blood cultures (bacteremia) at time of enrollment (current, meaning they have not received treatment and now have negative most-recent blood cultures).

Trial design

Design model

Parallel

Treatments tested in this trial

  • Vancomycin 1000 MG

    Drug

    Powdered, intrawound vancomycin 1000 mg at the time of definitive surgery for open fracture fixation in addition to the current best practice of intravenous antibiotics with irrigation and debridement

Treatment groups

350 Participants
are divided into 2 treatment groups
Group A: TreatmentExperimental treatment 1 intervention
Group B: ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Deep surgical site infection

A post-operative surgical infection requiring return to the operating room for irrigation and debridement with or without hardware removal/revision after the definitive fixation.

Time frame
Within six months of definitive surgical orthopedic fixation

Secondary outcomes

1

Superficial surgical site infection

A post-operative infection that required antibiotic treatment but no return to the operating room

Time frame
Within six months of definitive surgical orthopedic fixation
2

Hardware failure visualized either on imaging or found intra-operatively, until six months post definitive fixation

Hardware loosening, loss of fixation, hardware fracture, or hardware migration visualized either on imaging or found intra-operatively

Time frame
Up until six months following definitive fixation
3

Microbe sensitivity

In patients with deep surgical site infection, the gram stain and sensitivity and resistance to antibiotics of cultures taken intra-operatively in the take-back irrigation and debridement surgery

Time frame
Up until six months following definitive fixation
4

Fracture location

Whether the fracture is in the upper extremity: clavicle, humerus, radius, ulna, metacarpals and phalanges (fingers) versus lower extremity: femur, tibia, fibula, metatarsals, and phalanges (toes).

Time frame
At time of initial open fracture

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Manitoba

Lead sponsor

Health Sciences Centre, Winnipeg, Manitoba

Collaborator

This trial is not recruiting at the moment. You can still explore other options: